^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Lung Non-Squamous Non-Small Cell Cancer)
    New
    Excerpt:
    Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncol Ther
    Title:

    A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy

    Published date:
    05/15/2021
    Excerpt:
    Data were analyzed for the period from January 2015 to August 2019 for 49 patients with metastatic EGFR-mutated lung adenocarcinoma receiving first-line erlotinib-and-bevacizumab combination therapy...The combination of erlotinib and bevacizumab showed an 83.7% objective response rate and a 97.9% disease control rate. The median progression-free survival (PFS) and overall survival (OS) were 22.0 [95% CI (19.7-22.33)] and 47.6 [95% CI (38.87-56.37)] months, respectively, for all patients.
    DOI:
    10.1007/s40487-021-00152-6